# Racial Differences in Device-Detected Incident Atrial Fibrillation

Jack Goergen, MD<sup>1</sup> and Graham Peigh, MD, MSc<sup>1</sup>, Nathan Varberg, BS<sup>2</sup>, Paul Ziegler, MS<sup>2</sup>, Dana Soderlund, MPH<sup>2</sup>, Sadiya Khan, MD, MS<sup>1</sup>, Rod Passman, MD, MSCE<sup>1</sup>

<sup>1</sup>Northwestern University, Feinberg School of Medicine, Chicago, IL. <sup>2</sup>Medtronic Inc., Minneapolis, MN. Jack.Goergen@nm.org

## Background

- Despite having a greater prevalence of cardiovascular risk factors, prior research suggests Black individuals have a lower incidence of atrial fibrillation (AF) than White individuals.
- Most prior research relied on ECGs or ICD codes to determine the incidence of AF.
- Whether this paradox persists utilizing highly sensitive methods of AF diagnosis has not been well studied.


# Research Objective

• To compare rates of incident AF between Black individuals and White individuals as identified by cardiac implantable electronic devices (CIEDs) capable of continuous arrythmia detection.

#### Methods

- Retrospective analysis of Black and White individuals with no history of AF who had a CIED implanted between 01/01/2007 and 06/01/2019 (Figure 1).
- Patient demographics were collected from the Optum® electronic health record.
- Incidence of AF was determined via the Medtronic CareLink® database a database storing individual patients' heart rhythm data detected by their CIED.
- Primary endpoint: time to first device-detected AF lasting > 6
  minutes in one day.
- Analysis:
  - Kaplan-Meier survival analysis and Cox proportional hazards modelling was used to compare differences in incident AF between Black and White individuals.
  - Covariates in the adjusted models included age, sex, and comorbid conditions known to be AF risk factors, including hypertension, diabetes, heart failure, atherosclerotic cardiovascular disease, and obstructive sleep apnea.
  - Secondary analyses were performed to investigate the specific interactions between race, gender, age, and incident AF.





#### Results

- Of 88,427 patients included in analysis (69±13 years, 63% male), there were 80,382 (91%) White individuals and 8,045 Black individuals (9%). Differences in baseline characteristics are shown in Table 1.
- Over a mean of 2.2±1.7 years of monitoring, crude incidence of AF was greater among White compared with Black individuals (27.95 vs. 24.86 cases per 100 person years, p<0.001, Figure 2).</li>
- After adjusting for age, sex, and AF risk factors, the hazard of developing AF in the overall cohort was similar between Black and White individuals (Figure 3).
- Hazard varied by device type. In patients with ICDs, White individuals had a lower adjusted hazard of AF, but in patients with PPMs, White individuals had a greater adjusted hazard of AF (Figure 3).
- In the youngest quartile (18-62 years), Black individuals had a greater incidence of AF than White individuals. Within the second quartile (62-71 years), rates of incident AF were similar among White and Black individuals. However, among the third (71-79 years) and fourth (>79 years) quartiles of age, White individuals had a greater incidence of AF than Black individuals (Figure 4).

## Limitations

- Race was categorized according to the Optum EHR categorization, which was a nonuniform process across provider organizations.
- Patients with CIEDs are a specific population with a unique risk profile, and these results may not be generalizable to the broader population.
- We did not account for variable degrees of ventricular pacing within the cohort, a factor previously shown to impact incident AF.
- While CIEDs are highly sensitive and specific for the diagnosis of AF, there was no independent adjudication of AF diagnoses in the present study.

# Conclusions

- The present study demonstrates a similar adjusted hazard of incident AF between Black and White individuals with CIEDs, and a greater incidence of AF in young Black individuals.
- These results underscore the importance of appropriate inclusion of diverse populations in future AF trials and encourage clinicians to equitably consider risk of AF regardless of race.